BioCentury | Mar 10, 2021
Deals

Maverick takeout adds T cell-engagers to Takeda’s solid tumor toolkit

...unveiled during that year’s J.P. Morgan Healthcare Conference. The headliner was Takeda’s $5.2 billion acquisition of Ariad Pharmaceuticals Inc....
BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

...strategy at Merck & Co. Inc. (NYSE:MRK). Gansler was SVP, head of human resources at Ariad...
BioCentury | Jul 26, 2019
Product Development

Takeda's deals paint a picture of a turnaround in action

...least 61 option or in-licensing deals since the start of 2016, and acquired three companies: Ariad Pharmaceuticals Inc....
BioCentury | May 16, 2019
Clinical News

May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven

...gained the oral tyrosine kinase inhibitor targeting EGFR and HER2 mutations through its acquisition of Ariad Pharmaceuticals Inc....
BioCentury | Sep 28, 2018
Finance

Activating Akrevia

...were not disclosed. Prior to joining Akrevia, Clackson was president of R&D at oncology company Ariad Pharmaceuticals Inc....
BioCentury | Sep 28, 2018
Financial News

F-Prime, Atlas lead Akrevia's $30M series A

...did not disclose how much runway it will provide. Clackson was president of R&D at Ariad Pharmaceuticals Inc....
BioCentury | Sep 27, 2018
Financial News

F-Prime, Atlas lead Akrevia's $30M series A

...did not disclose how much runway it will provide. Clackson was president of R&D at Ariad Pharmaceuticals Inc....
BioCentury | Sep 14, 2018
Company News

Takeda to move U.S. headquarters to Boston area

...closer collaboration. Takeda already has a presence in Massachusetts -- it acquired Cambridge-based cancer company Ariad Pharmaceuticals Inc....
BioCentury | Sep 12, 2018
Company News

Takeda to move U.S. headquarters to Boston

...closer collaboration. Takeda already has a presence in Massachusetts -- it acquired Cambridge-based cancer company Ariad Pharmaceuticals Inc....
...under 1,000 employees, will "progressively consolidate" to the new location after the Shire deal closes. Mary Romeo Ariad Pharmaceuticals Inc. Shire...
BioCentury | Jul 25, 2018
Company News

Management Tracks: Albireo, ObsEva

...Inc. subsidiary and EVP of global commercial. She was EVP and chief commercial officer at Ariad Pharmaceuticals Inc....
Items per page:
1 - 10 of 693
BioCentury | Mar 10, 2021
Deals

Maverick takeout adds T cell-engagers to Takeda’s solid tumor toolkit

...unveiled during that year’s J.P. Morgan Healthcare Conference. The headliner was Takeda’s $5.2 billion acquisition of Ariad Pharmaceuticals Inc....
BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

...strategy at Merck & Co. Inc. (NYSE:MRK). Gansler was SVP, head of human resources at Ariad...
BioCentury | Jul 26, 2019
Product Development

Takeda's deals paint a picture of a turnaround in action

...least 61 option or in-licensing deals since the start of 2016, and acquired three companies: Ariad Pharmaceuticals Inc....
BioCentury | May 16, 2019
Clinical News

May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven

...gained the oral tyrosine kinase inhibitor targeting EGFR and HER2 mutations through its acquisition of Ariad Pharmaceuticals Inc....
BioCentury | Sep 28, 2018
Finance

Activating Akrevia

...were not disclosed. Prior to joining Akrevia, Clackson was president of R&D at oncology company Ariad Pharmaceuticals Inc....
BioCentury | Sep 28, 2018
Financial News

F-Prime, Atlas lead Akrevia's $30M series A

...did not disclose how much runway it will provide. Clackson was president of R&D at Ariad Pharmaceuticals Inc....
BioCentury | Sep 27, 2018
Financial News

F-Prime, Atlas lead Akrevia's $30M series A

...did not disclose how much runway it will provide. Clackson was president of R&D at Ariad Pharmaceuticals Inc....
BioCentury | Sep 14, 2018
Company News

Takeda to move U.S. headquarters to Boston area

...closer collaboration. Takeda already has a presence in Massachusetts -- it acquired Cambridge-based cancer company Ariad Pharmaceuticals Inc....
BioCentury | Sep 12, 2018
Company News

Takeda to move U.S. headquarters to Boston

...closer collaboration. Takeda already has a presence in Massachusetts -- it acquired Cambridge-based cancer company Ariad Pharmaceuticals Inc....
...under 1,000 employees, will "progressively consolidate" to the new location after the Shire deal closes. Mary Romeo Ariad Pharmaceuticals Inc. Shire...
BioCentury | Jul 25, 2018
Company News

Management Tracks: Albireo, ObsEva

...Inc. subsidiary and EVP of global commercial. She was EVP and chief commercial officer at Ariad Pharmaceuticals Inc....
Items per page:
1 - 10 of 693